These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35248947)

  • 1. Epoxymicheliolide inhibits osteoclastogenesis and resists OVX-induced osteoporosis by suppressing ERK1/2 and NFATc1 signaling.
    Long F; Chen R; Su Y; Liang J; Xian Y; Yang F; Lian H; Xu J; Zhao J; Liu Q
    Int Immunopharmacol; 2022 Jun; 107():108632. PubMed ID: 35248947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
    Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
    Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
    [No Abstract]   [Full Text] [Related]  

  • 3. Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway.
    Wu L; Liang J; Li J; Xu Y; Chen J; Su Y; Xian Y; Wei J; Xu J; Zhao J; Liu Q; Yang Y
    Eur J Pharmacol; 2022 May; 923():174908. PubMed ID: 35405113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption.
    Li S; Teguh D; Wu D; Liu L; Hu C; Yuan J; Inderjeeth CA; Xu J
    J Cell Physiol; 2023 Aug; 238(8):1823-1835. PubMed ID: 37334837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDK2 Deficiency Prevents Ovariectomy-Induced Bone Loss in Mice by Regulating the RANKL-NFATc1 Pathway During Osteoclastogenesis.
    Lee JM; Kim MJ; Lee SJ; Kim BG; Choi JY; Lee SM; Ham HJ; Koh JM; Jeon JH; Lee IK
    J Bone Miner Res; 2021 Mar; 36(3):553-566. PubMed ID: 33125772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
    Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
    Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andrographolide Inhibits Ovariectomy-Induced Bone Loss via the Suppression of RANKL Signaling Pathways.
    Wang T; Liu Q; Zhou L; Yuan JB; Lin X; Zeng R; Liang X; Zhao J; Xu J
    Int J Mol Sci; 2015 Nov; 16(11):27470-81. PubMed ID: 26593901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL-induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation.
    Xu Y; Song D; Lin X; Peng H; Su Y; Liang J; Hai N; Zhao J; Liu Q
    Free Radic Biol Med; 2023 Feb; 196():121-132. PubMed ID: 36649902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL-Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway.
    Wang Y; Li X; Zhou S; Li J; Zhu Y; Wang Q; Zhao F
    Oxid Med Cell Longev; 2022; 2022():7727006. PubMed ID: 36148414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydrotanshinone I attenuates estrogen-deficiency bone loss through RANKL-stimulated NF-κB, ERK and NFATc1 signaling pathways.
    Ma C; Mo L; Wang Z; Peng D; Zhou C; Niu W; Liu Y; Chen Z
    Int Immunopharmacol; 2023 Oct; 123():110572. PubMed ID: 37572501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis.
    Kim M; Kim HS; Kim JH; Kim EY; Lee B; Lee SY; Jun JY; Kim MB; Sohn Y; Jung HS
    BMC Complement Med Ther; 2020 Feb; 20(1):35. PubMed ID: 32024503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
    Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
    Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca
    Cao B; Dai X; Wang W
    J Cell Physiol; 2019 May; 234(5):6831-6841. PubMed ID: 30387123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of PPP1R15A alleviates osteoporosis via suppressing RANKL-induced osteoclastogenesis.
    Ding ZB; Chen Y; Zheng YR; Wang YY; Deng WD; Zheng JH; Yang Q; Chen ZY; Li LH; Jiang H; Li XJ
    Acta Pharmacol Sin; 2024 Apr; 45(4):790-802. PubMed ID: 38191913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Brown Algae
    Kim M; Park M
    Nutrients; 2022 Apr; 14(9):. PubMed ID: 35565651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
    Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
    Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway.
    Tan T; Li T; Xiang C; Ouyang Z
    Int Immunopharmacol; 2023 Mar; 116():109745. PubMed ID: 36702075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.